×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 2 Track 1: Business Impacts to IDMP
Session Chair(s)
Vada A. Perkins, DrSc, MSc
Vice President, Global Head of Regulatory Intelligence & Policy
Boehringer Ingelheim, United States
Explore some of the opportunities and challenges of addressing IDMP integration within the pharmaceutical environment. Discussion topics include collaborative processes and principles for successful assessment and implementation of an IDMP program, along with a case-study from a company perspective to provide lessons learned in their approach to IDMP to deliver business improvements.
Learning Objective : Ability to identify and ultimately plan for a synergistic IDMP/RIM program. Plan for and perform analysis on various processes in order to formulate an action plan for long term compliance. Describe and share with colleagues the long term goal of IDMP, how it's not just about data, as well has how other agency activities come into play.
Speaker(s)
Collaborative Processes for a Successful IDMP Program
Sue Metz
IRISS Forum, United States
President/CEO
IDMP Readiness – Status Based on Pharmaceutical Company Assessments in Europe
Thomas Hornbaek Svendsen, MS
NNIT A/S, Denmark
Managing Consultant
Sponsor Perspective Case Study
Christian A. Buckley, MBA, RAC
Astellas, United States
Associate Director, Regulatory Affairs
Have an account?